Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of signing the consent form
• People with an advanced solid tumour (such as pancreatic cancer, non-small cell lung cancer, stomach cancer, or colorectal cancer, among others) that has been confirmed by laboratory testing of tissue or cell samples, cannot be removed by surgery, and has either stopped responding to standard treatments, cannot be tolerated by the patient, or has no effective standard treatment available
• People who have at least one tumour that can be measured on a scan at the start of the study
• People whose general physical functioning is rated as largely normal or showing only minor limitations (confirm with trial site for exact scoring)
• People whose doctors estimate they have a life expectancy of at least 12 weeks at the start of the study
• People whose liver, kidney, blood, heart, and clotting test results fall within acceptable ranges as defined by the trial (confirm with trial site for specific values)
• Women who are not able to become pregnant, or women of childbearing age who have a negative pregnancy test and agree to use effective contraception or remain abstinent from the screening period until 90 days after the last dose; or men who agree to use effective contraception or remain abstinent from screening until 90 days after the last dose — and who agree not to donate sperm from the start of treatment until 6 months after the last dose
• People who understand the trial, sign the consent form willingly, and are able to attend all required visits and complete all study procedures

Who may not be able to join:

• Women who are pregnant or breastfeeding
• People who have difficulty swallowing
• People who cannot tolerate blood draws, or who have a history of fainting that the doctor considers clinically significant
• People with tumour-related pain that is not under control
• People who are allergic to or cannot tolerate the ingredients in the study drug
• People who have received radiation therapy to a target tumour within 4 weeks before starting the study drug, or who have received other anti-cancer treatments (such as chemotherapy, targeted therapy, or immunotherapy) within a defined period before starting (confirm with trial site for exact timeframes); or who have used herbal therapies with anti-cancer purposes within 1 week before starting
• People with a tumour that started in the brain or spinal cord, or whose cancer has spread to the brain — unless the brain involvement has been treated, has been stable for at least 3 months, and certain other conditions are met (confirm with trial site)
• People with uncontrolled fluid build-up around the lungs, heart, or abdomen that requires drainage more than once a month — though people with a permanent drainage tube in place may still be considered
• People with spinal cord compression that has not been treated or is still causing symptoms, unless it has been treated and has been stable on scans for at least 4 weeks before starting and requires no steroid treatment
• People who have had two or more separate cancers within the past 5 years — with some exceptions for certain early-stage or fully treated skin and cervical cancers
• People with an active tuberculosis infection found within the past year, or a past tuberculosis infection that was never properly treated
• People with interstitial lung disease or significant lung inflammation, including radiation-related lung damage that affects daily life or requires treatment
• People who have had a serious infection requiring hospitalisation within 4 weeks before starting, or an active infection requiring antibiotic treatment within 2 weeks before starting
• People with a significant history of heart or stroke-related conditions, including certain heart rhythm problems, heart failure, a heart attack, stroke, or other serious cardiovascular events within 6 months before starting; or uncontrolled high blood pressure or reduced heart pumping function (confirm with trial site for specific thresholds)
• People with certain active hepatitis B, hepatitis C, liver cirrhosis, or active syphilis infections (confirm with trial site for specific test thresholds)
• People with active autoimmune diseases (such as lupus or rheumatoid arthritis) that may flare up — with an exception for stable autoimmune thyroid conditions
• People with a history of immune deficiency conditions, including HIV; or those who have had an organ transplant from another person (bone marrow transplants from one's own cells may be acceptable if completed at least 3 months before screening)
• People who have had significant bleeding within 3 months before starting, or who coughed up meaningful amounts of blood within 4 weeks before starting; or who have had blood clot events such as stroke, deep vein thrombosis, or pulmonary embolism within 6 months before starting; or who are currently on blood-thinning medication
• People who have participated in another clinical trial involving an unapproved drug or treatment within 4 weeks (or 5 drug half-lives, whichever is longer) before starting
• People who have received a live or weakened vaccine within 4 weeks before starting, or plan to receive one during the study
• People who have used certain medications that strongly affect how the body processes drugs (specific CYP3A4 inhibitors or inducers) within 2 weeks before starting, or who will need to use them during the study (confirm with trial site for specific medications)
• People who have had major surgery within 4 weeks before starting, or who are expected to need major surgery during the study; or who have had minor or diagnostic surgery within 7 days before starting
• People who still have significant side effects from previous cancer treatments that have not sufficiently resolved — with some exceptions for hair loss, certain nerve-related side effects, and other conditions judged to be low risk by the doctor
• People with serious mental health conditions, alcohol misuse, or drug misuse that could affect their ability to follow the trial requirements, or any other condition the doctor feels makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.